IL1RL1 and asthma: Astegolimab, a selective inhibitor of the IL-33 receptor ST2, was shown to attenuate the asthma exacerbation rate at a subcutaneous dose of 70 mg in a phase 2 trial in patients with severe asthma, including those with low eosinophils (71).